Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole

Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. However, the evidence of its use in children and adolescents is rather sparse. The aim of this case study is to d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical psychopharmacology 2016-10, Vol.36 (5), p.496-499
Hauptverfasser:	Jakobsen, Klaus Damgaard, Bruhn, Christina Hedegaard, Pagsberg, Anne-Katrine, Fink-Jensen, Anders, Nielsen, Jimmi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antipsychotic Agents - adverse effects Aripiprazole - adverse effects Attention Deficit Disorder with Hyperactivity - drug therapy Autism Spectrum Disorder - drug therapy Child Child, Preschool Databases, Factual Denmark Drug-Related Side Effects and Adverse Reactions - physiopathology Female Humans Male Neurodevelopmental Disorders - drug therapy Obsessive-Compulsive Disorder - drug therapy Psychotic Disorders - drug therapy Schizophrenia - drug therapy Tourette Syndrome - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. However, the evidence of its use in children and adolescents is rather sparse. The aim of this case study is to discuss adverse drug reaction (ADR) reports concerning aripiprazole-associated neurological and psychiatric events in children and adolescents. The ADR report database at Danish Medicines Agency was searched for all ADRs involving children and adolescents (
ISSN:	0271-0749 1533-712X
DOI:	10.1097/JCP.0000000000000548